Abstract:ID 92155 Poster Board 478 The Glucagon-like peptide 1 receptor (GLP-1R) belongs to the Class B G-protein coupled receptors (GPCRs) and is a well-established target for treating type 2 diabetes. Recent clinical-trial data suggest that GLP-1R agonistic drugs not only significantly reduce body weight in individuals with obesity, but may also offer protection against serious heart disease and drug/alcohol addiction related issues. Consequently, GLP-1R has become one of the most intriguing and extensively studied Class B GPCRs. Although GLP-1R agonist-based therapies, including various GLP-1 analog drugs, are highly successful and available in the market, most are peptidic in nature and require intravenous ( iv ) mode of administration. Thus, it remains a challenge to develop nonpeptidic agonist drugs targeting GLP-1R. A promising approach, involves the development of small molecule positive allosteric modulators (PAMs) of GLP-1R, which have a greater potential for more convenient oral ( po ) administration. Building upon our prior work that identified two 2-aminothiophene-based small-molecule PAMs of GLP-1R, we conducted a series of structural SAR optimizations, as well as in vitro and in vivo studies. This effort led to the identification of 2-aminothiophene derivative, I-187 (MW 299), which exhibited an approximately 2-fold increase in insulin secretion at 5 μM when combined with the GLP-1 peptide at 10 nM. I n vivo studies using CD1 mice revealed a 50% reduction in glucose levels after 60 minutes at a dose of 10 mg/kg b.w. More notably, co-treatment with sitagliptin, an inhibitor of the GLP-1 degrading enzyme dipeptidyl peptidase IV, demonstrated that I-187 synergistically lowered blood glucose levels by approximately 75% after 60 minutes, confirming its effectiveness as a PAM of GLP-1R. These promising results, coupled with the favorable drug-like properties of the compound, suggest that I-187 is a compelling lead compound for future drug development. Furthermore, this approach can potentially be applied to the development of allosteric modulation of other GPCRs. This work was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R15GM140406.

Affinity selection of double-click triazole libraries for rapid discovery of allosteric modulators for GLP-1 receptor

Molecular Insights into Ago-Allosteric Modulation of the Human Glucagon-Like Peptide-1 Receptor

Discovery of Novel Allosteric Modulators Targeting an Extra-Helical Binding Site of GLP-1R Using Structure- and Ligand-Based Virtual Screening

Allosteric Modulators Enhancing GLP-1 Binding to GLP-1R via a Transmembrane Site

Discovery of Non-Peptide GLP-1 Positive Allosteric Modulators from Natural Products: Virtual Screening, Molecular Dynamics, ADMET Profiling, Repurposing, and Chemical Scaffolds Identification

Recent Advances in the Drug Discovery and Development of Dualsteric/ Bitopic Activators of G Protein-Coupled Receptors.

Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor

Structural basis for the therapeutic advantage of dual and triple agonists at the human GIP, GLP-1 or GCG receptors

In Silico Ligand Docking Approaches to Characterise the Binding of Known Allosteric Modulators to the Glucagon-Like Peptide 1 Receptor and Prediction of ADME/Tox Properties

Molecular basis of enhanced GLP-1 signaling mediated by GLP-1(9-36) in conjunction with LSN3318839

Binding sites and design strategies for small molecule GLP-1R agonists

Polypharmacy through Phage Display: Selection of Glucagon and GLP-1 Receptor Co-agonists from a Phage-Displayed Peptide Library

Developing 2-Aminothiophene Derivatives as Positive Allosteric Modulators of Glucagon-Like Peptide 1 Receptor

3-Benzyl-1,3-oxazolidin-2-ones As Mglur2 Positive Allosteric Modulators: Hit-to Lead and Lead Optimization

Synthesis and biological studies of 2-aminothiophene derivatives as positive allosteric modulators of glucagon-like peptide 1 receptor

Optimized Methods for the Production and Bioconjugation of Site-Specific, Alkyne-Modified Glucagon-like Peptide-1 (GLP-1) Analogs to Azide-Modified Delivery Platforms Using Copper-Catalyzed Alkyne-Azide Cycloaddition

Discovery of Novel 5,6-Dihydro-1,2,4-triazine Derivatives as Efficacious Glucagon-Like Peptide-1 Receptor Agonists

Identifying glucagon-like peptide-1 mimetics using a novel functional reporter gene high-throughput screening assay.

A platform for the rapid synthesis of molecular glues (Rapid-Glue) under miniaturized conditions for direct biological screening

Focused Combinatorial Library Design Based on Structural Diversity, Druglikeness and Binding Affinity Score.

The impact of click chemistry in medicinal chemistry.